Your sector of activity
Genomics research
Clinical and Translational Research
Biopharma & CRO
Our Services
Genome, Exome, Panel
RNA Seq
Methylation
Methylation by sequencing
Methylation using Illumina MethEPIC
Sequencing Only
Genotyping
Nucleic Acid Isolation
Bioinformatics analysis
Tumor Genomic Analysis: Mercury
Gene Expression Analysis: Galileo
Advanced Genomic Analysis Service: GeCo
Constitutional genomic analysis: VarSome Clinical
About us
Our History
Certifications
Board of Directors
Our Management Team
Job Offers
Communication
News
Events
Scientific Publications
Investors
Investor Relations
Annual General Meeting
Financial documents
Financial Communications
Archives
Financial Reports Archives
Archived Press Releases
Liquidity contract
Oncodna friendly takeover bid
Contact
Search
Financial Reports
2024
Half-year financial statements 2024
Half-year report 2024
2023
Financial statements & notes 2023
Annual Management Report 2023
Half-year financial statements 2023
Half-year report 2023
2022
Financial statements & Notes 2022
Annual management report
2022
Half-year financial statements 2022
Half-year report 2022
2021
Financial statements & notes 2021
Annual Management Report 2021
2021 interim financial statements
Half-year report 2021
Consult the Archives
Directors' titles
Date of operation
Type of operation
Registrant
Number of shares
Amount of operation
June 12, 2014
Acquisition
B. Courtieu
1 978
10 681,20 €
July 27, 2010
Acquisition
B. Courtieu
2 046
11 969,10 €
Declaration
Share Buyback Program
share-purchase-program-description-authorized-by-general-meeting-shareholders-19-june-2013